Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $48.32 USD
Change Today -0.14 / -0.29%
Volume 3.5M
ABT On Other Exchanges
Symbol
Exchange
Mexico
SIX Swiss Ex
London
Sao Paulo
Frankfurt
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABT) Snapshot

Open
$48.36
Previous Close
$48.46
Day High
$48.52
Day Low
$48.09
52 Week High
04/23/15 - $48.62
52 Week Low
04/28/14 - $37.78
Market Cap
72.9B
Average Volume 10 Days
4.8M
EPS TTM
$1.76
Shares Outstanding
1.5B
EX-Date
04/13/15
P/E TM
27.4x
Dividend
$0.96
Dividend Yield
1.90%
Current Stock Chart for ABBOTT LABORATORIES (ABT)

abbott laboratories (ABT) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices to treat vascular diseases. Abbott Laboratories also offers blood, continuous, and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes under the FreeStyle brand; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

73,000 Employees
Last Reported Date: 04/22/15
Founded in 1888

abbott laboratories (ABT) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $2.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.0M
Executive Vice President of Medical Devices
Total Annual Compensation: $696.8K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $690.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2014.

abbott laboratories (ABT) Key Developments

Abbott Laboratories Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for the Full Year 2015; Provides Earnings Guidance for the Second Quarter of 2015

Abbott Laboratories announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, net sales were $4,897 million against $4,755 million a year ago. Operating earnings was $610 million against $365 million a year ago. Earnings from continuing operations before taxes were $653 million against $341 million a year ago. Earnings from continuing operations were $529 million against $224 million a year ago. Net earnings were $2,292 million against $375 million a year ago. Diluted earnings per common share from continuing operations were $0.35 against $0.14 a year ago. Diluted earnings per common share was $1.51 against $0.24 a year ago. Earnings from continuing operations before taxes, as adjusted were $887 million against $660 million a year ago. Net earnings from continuing operations as adjusted were $719 million against $535 million a year ago. Diluted earnings per share from continuing operations, as adjusted were $0.47 against $0.34 a year ago. For the full year 2015, ongoing EPS guidance remains unchanged. The company’s full-year 2015 guidance range for earnings per share from continuing operations, excluding specified items, remains unchanged at $2.10 to $2.20, representing strong growth at the mid-point of the guidance range. Including net specified items, projected earnings per share from continuing operations under U.S. Generally Accepted Accounting Principles (GAAP) would be $1.33 to $1.43 for the full year 2015. Sales growth is expected in the low single digits for the full year 2015. The company now forecast adjusted gross margin ratio of around 57.5% of sales for the full year and continue to expect to expand full year adjusted operating margins by over 100 basis points in 2015. For the second quarter of 2015, the company forecast ongoing EPS of $0.49 to $0.51, reflecting double-digit underlying growth, largely offset by the impact of significant foreign exchange headwinds on operating results. The company forecast operational sales growth in the low double digits in the second quarter. At current exchange rate, The company expects a negative impact from exchange of somewhat above 8%, resulting in reported sales in the low single digits. The company forecast an adjusted gross margin ratio of around 57.5% of sales.

Abbott Laboratories Receives U.S. FDA Clearance for Freestyle Precision Neo Blood Glucose Monitoring System at Major U.S. Retailers

Abbott Laboratories announced that its blood glucose meter with high accuracy is available over-the-counter at major U.S. retailers at a lower cost than other branded meters and test strips, and without the need for insurance paperwork and copays often needed to purchase branded diabetes supplies. This new meter, the FreeStyle Precision Neo Blood Glucose Monitoring System, received Food and Drug Administration (FDA) clearance and is now available at a cost of between $14-$17 for 25 strips and a one-time fee for the meter, which ranges from $22-$28. In addition, the process associated with healthcare insurance paperwork can be a challenge for some individuals. To help provide a solution, Abbott developed FreeStyle Precision Neo the first system from Abbott's FreeStyle family of products that is available over the counter with preferred copay pricing, giving patients the option to pay out of pocket to obtain their monitor and test strips. The FreeStyle Precision Neo System features include: Monitor's memory holds up to 1,000 readings; Slim design; the device is thinner than a 'AAA' battery; large touchscreen display with simple icons; easy-to-read numbers; fast, five-second test time; small blood sample size; and E-Ink screen, short for electrophoretic ink, which displays the appearance of a printed page.

Abbott and Sekisui Agree to Offer Coagulation Testing for Laboratories Worldwide

Abbott and Sekisui announced an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. As per the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the United States, Europe and other regions that recognize CE Mark. Coagulation testing helps clinicians in assessing people before many medical treatments and in monitoring those who take medications that can affect clotting. It is also useful in the diagnosis of blood-related disorders, such as hemophilia and thrombosis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:US $48.32 USD -0.14

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.07 USD +1.82
AstraZeneca PLC 4,750 GBp -80.50
Danaher Corp $83.30 USD -1.39
Teva Pharmaceutical Industries Ltd $64.41 USD +1.16
Thermo Fisher Scientific Inc $130.02 USD +0.47
View Industry Companies
 

Industry Analysis

ABT

Industry Average

Valuation ABT Industry Range
Price/Earnings 36.5x
Price/Sales 3.6x
Price/Book 3.4x
Price/Cash Flow 15.3x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit www.abbott.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.